2021
Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment
Wallach JD, Deng Y, McCoy RG, Dhruva SS, Herrin J, Berkowitz A, Polley EC, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Shah ND, Ross JS, Lyon TD. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Network Open 2021, 4: e2130587. PMID: 34677594, PMCID: PMC8536955, DOI: 10.1001/jamanetworkopen.2021.30587.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsSecondary end pointsMyocardial infarctionClinical trialsCardiovascular diseaseProstate cancerCardiovascular eventsEnd pointRisk of MACELarge US administrative claims databasePropensity-matched cohort studyUS administrative claims databasePropensity score-matched patientsAdverse cardiovascular eventsPrimary end pointAdministrative claims databaseProportional hazards regressionRandomized clinical trialsAdministrative claims dataTrial eligibility criteriaMedicare Advantage beneficiariesProstate cancer treatmentReal-world evidenceElectronic health recordsCardiovascular outcomes
2016
Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications
Gershman B, Van Houten HK, Herrin J, Moreira DM, Kim SP, Shah ND, Karnes RJ. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications. European Urology 2016, 71: 55-65. PMID: 26995328, DOI: 10.1016/j.eururo.2016.03.015.Peer-Reviewed Original ResearchConceptsRate of biopsyProstate-specific antigen (PSA) screeningPredictors of complicationsPostbiopsy complicationsUSPSTF recommendationsAntigen screeningProstate biopsyRelative morbidityScreening TrialUS Preventive Services Task Force (USPSTF) recommendationOvarian Cancer Screening TrialAmerican Urological Association guidelinesMorbidity of biopsyPrior fluoroquinolone useEuropean Randomized StudyCancer Screening TrialInterrupted time series analysisProportion of menTask Force recommendationsInfectious complicationsAnticoagulant useComplication rateUnderwent biopsyRandomized studyScreening guidelines
2014
Reply to K. Quan et al, S.P. Collins et al, C.R. King et al, S. Arcangeli et al, D.B. Fuller, and D. Vordermark
Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Reply to K. Quan et al, S.P. Collins et al, C.R. King et al, S. Arcangeli et al, D.B. Fuller, and D. Vordermark. Journal Of Clinical Oncology 2014, 32: 3456-3457. PMID: 25185090, DOI: 10.1200/jco.2014.57.6108.Peer-Reviewed Original ResearchStereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity
Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity. Journal Of Clinical Oncology 2014, 32: 1195-1201. PMID: 24616315, PMCID: PMC3986382, DOI: 10.1200/jco.2013.53.8652.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyIntensity-modulated radiation therapyGU toxicityIMRT patientsRadiation therapyTreatment initiationProstate cancerTreatment costsSBRT patientsMedicare beneficiaries ageBody radiation therapyMean treatment costProstate cancer treatmentRandom-effects modelUrinary incontinenceBiologic doseRandomized trialsRetrospective studyPrimary treatmentLower treatment costsBeneficiaries agePatientsMedicare programRadiation therapy treatmentProspective correlation
2013
Response
Yu JB, Soulos PR, Herrin J, Cramer LD, Roberts KB, Gross CP. Response. Journal Of The National Cancer Institute 2013, 105: 748-749. PMID: 23814886, DOI: 10.1093/jnci/djt076.Peer-Reviewed Original Research
2012
Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity
Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, Gross CP. Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. Journal Of The National Cancer Institute 2012, 105: 25-32. PMID: 23243199, PMCID: PMC3536640, DOI: 10.1093/jnci/djs463.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiotherapyProstate cancerMedicare beneficiariesGenitourinary toxicityEarly toxicityProton radiotherapyMultivariable logistic regressionPatterns of careMain outcome measuresType of radiotherapyMedicare reimbursementClinical benefitRetrospective studyPRT patientsOutcome measuresComprehensive cohortPRT useIMRT patientsPatientsSociodemographic characteristicsRadiotherapyCancerLogistic regressionMonthsSignificant differences